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Background: Radiofrequency ablation of renal artery nerves has been shown to reduce blood pressure (BP) in patients with severe, treatment-
resistant hypertension (rHTN, BP uncontrolled on at least 3 antihypertensive drugs). Longer follow-up of subjects undergoing renal denervation (RDN) 
is essential to establish the long-term safety and reliability of this novel treatment intervention.
methods: The Symplicity™ HTN-2 trial randomized subjects with rHTN and systolic BP ≥160 mm Hg to treatment by RDN or to maintenance 
on prior therapy. Control subjects were eligible to crossover to RDN at 6 months. All subjects were followed for 2 years (18 months post-RDN for 
crossover patients) to assess long-term effectiveness and safety of RDN.
results: At baseline, more crossover than RDN subjects were female (60% vs 35%), and 40% of the RDN and 30 % of the crossover group subjects 
had type 2 diabetes. BP was significantly lower than baseline at each time point (table). Pulse pressure was reduced -18.5 in the RDN group at 24 
months and -17.6 in the crossover group at 18 month (p<0.01 for both). Heart rate was reduced by renal denervation (table), presumably due to 
central sympathetic inhibition from afferent nerve ablation. No device-related serious adverse events occurred.
conclusions: RDN with the Symplicity catheter consistently reduced systolic BP by 28-32 mm Hg over 2 years with no safety concerns.
 
